NRx Pharmaceuticals, Inc. Q2 FY2026 earnings call

Pipeline & Regulatory Progress

• Preservative-free ketamine ANDA (Ketafree): Completed the first review cycle with the FDA, with only one remaining major deficiency related to the vial's luer lock component. The required manufacturer attestation has been submitted to the FDA, the company is targeting 2026 approval, and 5 million units of launch stock have already been ordered from the manufacturer.
• NRX100 (depression treatment NDA): Development is supported by new White House and congressional guidance directing the FDA to use real-world evidence for ketamine and psychedelic product approvals. Data from 65,000 patients shows intravenous ketamine has greater or comparable efficacy, with faster onset, than intranasal S-ketamine. The company is finalizing the NDA and targeting 2027 approval.
• NRX101: Selected as prime contractor for the DARPA-funded SPARC EMS trial, an FDA-approved phase 2/3 trial combining NRX101 with robotic TMS for treatment-resistant depression. The trial will enroll 240 patients at HOPE clinics and Harvard McLean Hospital, plus an additional 160 patients at U.S. military treatment facilities; contract negotiations are ongoing, and the trial is fully funded by the U.S. military. This expands NRX101's potential addressable market from just suicidal bipolar depression to over 15 million U.S. patients with treatment-resistant depression.
• Genuro Asset Acquisition & ALS Program: Completed acquisition of the Genuro patent and drug portfolio via Swiss court approval in June 2026. The portfolio includes two clinical-stage monoclonal antibodies: GNK301, a potential first disease-modifying treatment for ALS developed in partnership with the NIH, and Temelimab, which is being explored for schizophrenia, multiple sclerosis, and type 1 diabetes. GNK301's first-in-human trial is targeted for July 2027, and the program has already passed the first round of Congressional Directed Medical Research Program funding.

Commercial & Operational Growth

• HOPE Therapeutics Clinics: Expanded the clinic footprint to 5 locations in Florida, with plans for further expansion via adding aligned partner clinics. The SPARC trial's robotic TMS platform gives HOPE a differentiated competitive position focused on precision, clinical excellence, and improved patient outcomes compared to traditional handheld TMS.

NRX Pharmaceuticals did not break out financial performance for distinct product segments in this earnings call. Only consolidated company-level financial results were provided: for the first half of 2026, the company reported a net loss of $18 million (down from a $23.1 million net loss in H1 2025), and a net operating loss of $11.3 million (up from a $7.6 million net operating loss in H1 2025). As of June 30, 2026, the company held $26.7 million in cash and cash equivalents, up from $7.8 million at the end of 2025, driven by a $22 million gross public offering of common stock completed in the period.

• Management confirmed that existing cash resources, combined with expected future clinic revenue growth and access to the company's active at-the-market offering facility, are sufficient to fund operations for at least 12 months from the date of the call.
• Regulatory approval guidance is maintained: preservative-free ketamine (Ketafree) is still targeted for 2026 approval, and NRX100 is still targeted for 2026 NDA submission/2027 approval.
• GNK301 (ALS) maintains its current guidance of a first-in-human trial in July 2027.

No specific material risks or operational failures were explicitly discussed by management on the call. The standard disclaimer was provided at the opening of the call noting that all forward-looking statements are subject to inherent risks and uncertainties that could cause actual results to differ materially from expectations, with additional risk factors detailed in the company's SEC filings.

Q: How will the company manage the potential overlap between launching approved Ketafree (preservative-free ketamine ANDA) and the upcoming NRX100 NDA for depression, given they are both ketamine-based products?

A: Ketafree and NRX100 are legally distinct products under U.S. regulation, with separate NDC numbers and different commercial pathways. Ketafree is formulated to match the reference drug Ketalar for the existing $750 million hospital/anesthetic pain control market, and its label will never include a depression indication, so it will not compete with or be substitutable for NRX100 if NRX100 gains insurance reimbursement for depression treatment.

Q: Does the DARPA-funded SPARC TMS trial for NRX101 in treatment-resistant depression change the company's regulatory priority or timeline for the existing NRX101 NDA for suicidal bipolar depression?

A: DARPA's funding supports the clinical research, not regulatory activities, but the opportunity massively expands NRX101's market potential. Management still prioritizes pursuing both indications: the existing breakthrough therapy designation for suicidal bipolar depression addresses an unmet need for hundreds of thousands of patients, and the company will evaluate pursuing both indications together if sufficient resources are available.

Q: Will the GNK301 ALS program require dilutive funding from NRX to reach its July 2027 first-in-human trial milestone, or will it use non-dilutive sources?

A: The company's current raised capital is prioritized for launching the ketamine product franchise. GNK301 is partnered with the NIH, which shares patent ownership, and there is substantial existing federal and philanthropic funding available for ALS research. The program already passed the first round of the Congressional Directed Medical Research Program, and management expects all development for GNK301 to be funded through non-dilutive government and philanthropic sources.

Q: Is it too early to consider international commercial or development opportunities for NRX's pipeline?

A: There are already existing international opportunities for the ketamine franchise, and NRX101 has broad worldwide patent coverage. The Genuro assets originated internationally, and while some patent lapsed during prior bankruptcy, extensive global patent protection remains for the portfolio. If clinical programs are successful, management expects all pipeline assets will be developed as global products.